Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Phase 3
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Gleolan
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- NX Development Corp
- Target Recruit Count
- 170
- Registration Number
- NCT05804370
- Locations
- 🇺🇸
Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, United States
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Phase 3
Completed
- Conditions
- Meningioma
- Interventions
- Drug: Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- NX Development Corp
- Target Recruit Count
- 108
- Registration Number
- NCT04305470
- Locations
- 🇺🇸
Swedish Medical Center, Englewood, Colorado, United States
🇺🇸NYU Langone Health, Brooklyn, New York, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath